Tower Research Capital LLC TRC Purchases Shares of 2,860 Atara Biotherapeutics Inc (NASDAQ:ATRA)

Tower Research Capital LLC TRC acquired a new stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 2,860 shares of the biotechnology company’s stock, valued at approximately $40,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Atara Biotherapeutics by 59.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,010 shares during the period. Aperio Group LLC purchased a new stake in shares of Atara Biotherapeutics in the 2nd quarter valued at approximately $63,000. Marshall Wace LLP purchased a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $284,000. Bank of Montreal Can increased its position in shares of Atara Biotherapeutics by 81.1% in the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 3,723 shares during the last quarter. Finally, Oppenheimer & Co. Inc. raised its holdings in shares of Atara Biotherapeutics by 15.2% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 1,340 shares in the last quarter.

Shares of Atara Biotherapeutics stock opened at $13.83 on Wednesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $13.01 and a 200-day simple moving average of $16.05. The stock has a market cap of $769.48 million, a price-to-earnings ratio of -2.62 and a beta of 2.04. Atara Biotherapeutics Inc has a 12-month low of $10.38 and a 12-month high of $43.94.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.40) by $0.09. On average, analysts forecast that Atara Biotherapeutics Inc will post -5.45 earnings per share for the current fiscal year.

In other Atara Biotherapeutics news, insider Joe Newell sold 3,500 shares of the company’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $13.51, for a total value of $47,285.00. Following the completion of the transaction, the insider now owns 57,998 shares in the company, valued at $783,552.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Citigroup set a $14.00 price objective on shares of Atara Biotherapeutics and gave the stock a “hold” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. lowered Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $43.00 to $22.00 in a report on Friday, November 8th. Goldman Sachs Group cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their price target for the company from $14.00 to $9.00 in a research note on Friday, September 27th. Mizuho set a $43.00 price target on Atara Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday, September 18th. Finally, Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company’s stock. Atara Biotherapeutics currently has a consensus rating of “Buy” and an average target price of $28.22.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: Understanding Specialty Certificates of Deposit

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.